Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs

被引：9

作者：

Guilleminault, Laurent ^{[1
,3
]}

Carre, Philippe ^{[1
]}

Beau-Salinas, Frederique ^{[2
]}

Taille, Camille ^{[4
,6
]}

Dieude, Philippe ^{[5
]}

Crestani, Bruno ^{[4
,6
]}

Diot, Patrice ^{[1
,3
]}

Marchand-Adam, Sylvain ^{[1
,3
]}

机构：

[1] CHRU Tours, Hop Bretonneau, Serv Pneumol & Explorat Fonct Resp, F-37032 Tours, France

[2] CHRU Tours, Dept Clin Pharmacol, Reg Ctr Pharmacovigilance, F-37032 Tours, France

[3] Univ Tours, INSERM, Unite U618, Fac Med, Tours, France

[4] Hop Bichat Claude Bernard, APHP, Serv Pneumol, F-75877 Paris 18, France

[5] Hop Bichat Claude Bernard, APHP, Serv Rhumatol, F-75877 Paris 18, France

[6] Univ Paris 05, INSERM, Unite U700, Fac Xavier Bichat, Paris, France

来源：

CHEST | 2011年 / 140卷 / 04期

关键词：

BLOCKADE;

D O I：

10.1378/chest.10-2350

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

We report five cases of asthma unmasked by antitumor necrosis factor (TNF)-alpha-blocking drugs. Asthma symptoms appeared within an average of 4 months (range 1-24 months) after starting the anti-TNF-alpha treatment for inflammatory disease. The patients did not appear to be predisposed to asthma except for one patient who had asthma during childhood. Four patients stopped anti-TNF-alpha-blocking drugs with an improvement of symptoms within 1 to 5 months. In the patient with a history of childhood asthma, respiratory symptoms recurred when another anti-TNF-alpha therapy was started. Asthma control was achieved with inhaled steroids, allowing anti-TNF-alpha treatment to continue. The biotherapy was maintained for the fifth patient in association with inhaled steroids. The path-physiologic mechanisms are unknown but are probably more complex than the T helper 1/T helper 2 imbalance suggested in the literature, and further studies are required. CHEST 2011; 140(4):1068-1071

引用

页码：1068 / 1071

页数：4

共 50 条

[1] Anti-tumor necrosis factor-α in asthma
Erin, Edward M.
Kon, Onn Min
Barnes, Peter J.
Hansel, Trevor T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (03) : 288 - 289
[2] Tumor Necrosis Factor- αA Promising Therapeutic Target for Asthma?
Enrico Heffler
Mike Berry
Ian D. Pavord
BioDrugs, 2007, 21 : 345 - 349
[3] Tumor necrosis factor-α -: A promising therapeutic target for asthma?
Heffler, Enrico
Berry, Mike
Pavord, Ian D.
BIODRUGS, 2007, 21 (06) : 345 - 349
[4] Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome
David Raveh
Ovadia Shemesh
Yaakov Jack Ashkenazi
Robert Winkler
Vivian Barak
Pediatric Nephrology, 2004, 19 : 1281 - 1284
[5] Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome
Raveh, D
Shemesh, O
Ashkenazi, Y
Winkler, R
Barak, V
PEDIATRIC NEPHROLOGY, 2004, 19 (11) : 1281 - 1284
[6] Leukocytoclastic vasculitis associated with tumor necrosis factor-α blocking agents
Mohan, N
Edwards, ET
Cupps, TR
Slifman, N
Lee, JH
Siegel, JN
Braun, MM
JOURNAL OF RHEUMATOLOGY, 2004, 31 (10) : 1955 - 1958
[7] Association of tumor necrosis factor-α and neutrophilic inflammation in severe asthma
Nagata, M
Kikuchi, S
Kikuchi, I
Hagiwara, K
Kanazawa, M
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S61 - S61
[8] Minocycline inhibits neurogenic inflammation by blocking the effects of tumor necrosis factor-
Gong, Kerui
Zou, Xiaoju
Fuchs, Perry N.
Lin, Qing
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (09): : 940 - 949
[9] Tumor necrosis factor-α-converting enzyme and tumor necrosis factor-α in human dilated cardiomyopathy
Satoh, M
Nakamura, M
Saitoh, H
Satoh, H
Maesawa, C
Segawa, N
Tashiro, A
Hiramori, K
CIRCULATION, 1999, 99 (25) : 3260 - 3265
[10] The gene polymorphism of tumor necrosis factor-β, but not that of tumor necrosis factor-α, is associated with the prognosis of sarcoidosis
Yamaguchi, E
Itoh, A
Hizawa, N
Kawakami, Y
CHEST, 2001, 119 (03) : 753 - 761

← 1 2 3 4 5 →